These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
499 related articles for article (PubMed ID: 12593474)
1. Pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in therapy control of patients with small-cell lung cancer. Schneider J; Philipp M; Salewski L; Velcovsky HG Clin Lab; 2003; 49(1-2):35-42. PubMed ID: 12593474 [TBL] [Abstract][Full Text] [Related]
2. ProGRP and NSE in therapy monitoring in patients with small cell lung cancer. Wójcik E; Kulpa JK; Sas-Korczyńska B; Korzeniowski S; Jakubowicz J Anticancer Res; 2008; 28(5B):3027-33. PubMed ID: 19031951 [TBL] [Abstract][Full Text] [Related]
3. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases. Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318 [TBL] [Abstract][Full Text] [Related]
5. Are levels of pro-gastrin-releasing peptide or neuron-specific enolase at relapse prognostic factors after relapse in patients with small-cell lung cancer? Hirose T; Okuda K; Yamaoka T; Ishida K; Kusumoto S; Sugiyama T; Shirai T; Ohnshi T; Ohmori T; Adachi M Lung Cancer; 2011 Feb; 71(2):224-8. PubMed ID: 20537424 [TBL] [Abstract][Full Text] [Related]
6. Value of tumour and inflammatory markers in lung cancer. Oremek GM; Sauer-Eppel H; Bruzdziak TH Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794 [TBL] [Abstract][Full Text] [Related]
7. Fuzzy logic-based tumor marker profiles improved sensitivity of the detection of progression in small-cell lung cancer patients. Schneider J; Peltri G; Bitterlich N; Philipp M; Velcovsky HG; Morr H; Katz N; Eigenbrodt E Clin Exp Med; 2003 Feb; 2(4):185-91. PubMed ID: 12624710 [TBL] [Abstract][Full Text] [Related]
8. [Clinical significance of ProGRP31-98 in patients with small-cell lung cancer]. Yang J; Li R; Li A Zhonghua Zhong Liu Za Zhi; 2000 May; 22(3):216-8. PubMed ID: 11778234 [TBL] [Abstract][Full Text] [Related]
9. ProGRP: a new biomarker for small cell lung cancer. Molina R; Filella X; Augé JM Clin Biochem; 2004 Jul; 37(7):505-11. PubMed ID: 15234231 [TBL] [Abstract][Full Text] [Related]
10. Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer. Holdenrieder S; von Pawel J; Dankelmann E; Duell T; Faderl B; Markus A; Siakavara M; Wagner H; Feldmann K; Hoffmann H; Raith H; Nagel D; Stieber P Clin Cancer Res; 2008 Dec; 14(23):7813-21. PubMed ID: 19047109 [TBL] [Abstract][Full Text] [Related]
11. [Tumor markers in lung cancer]. Niho S; Shinkai T Gan To Kagaku Ryoho; 2001 Dec; 28(13):2089-93. PubMed ID: 11791391 [TBL] [Abstract][Full Text] [Related]
12. [Pre-treatment and treatment-induced neuron-specific enolase in patients with small-cell lung cancer: an open prospective study]. Emin Erbaycu A; Gunduz A; Batum O; Zeren Ucar Z; Tuksavul F; Zeki Guclu S Arch Bronconeumol; 2010 Jul; 46(7):364-9. PubMed ID: 20537457 [TBL] [Abstract][Full Text] [Related]
13. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients. Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320 [TBL] [Abstract][Full Text] [Related]
14. Pro-gastrin-releasing peptide(31-98) is a specific tumor marker in patients with small cell lung carcinoma. Miyake Y; Kodama T; Yamaguchi K Cancer Res; 1994 Apr; 54(8):2136-40. PubMed ID: 8174119 [TBL] [Abstract][Full Text] [Related]
15. [Evaluation of tumor markers in the management of small cell lung cancer]. Ariyoshi Y Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):959-65. PubMed ID: 2839115 [TBL] [Abstract][Full Text] [Related]
16. Serum levels of pro-gastrin-releasing peptide for follow-up of patients with small cell lung cancer. Okusaka T; Eguchi K; Kasai T; Kurata T; Yamamoto N; Ohe Y; Tamura T; Shinkai T; Saijo N Clin Cancer Res; 1997 Jan; 3(1):123-7. PubMed ID: 9815547 [TBL] [Abstract][Full Text] [Related]
17. Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC). Shibayama T; Ueoka H; Nishii K; Kiura K; Tabata M; Miyatake K; Kitajima T; Harada M Lung Cancer; 2001 Apr; 32(1):61-9. PubMed ID: 11282430 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of neuron-specific enolase, tissue polypeptide antigen, and carcinoembryonic antigen as markers for staging and monitoring response to therapy of lung cancer. Spinazzi A; Soresi E; Boffi R; Nonis A; Noseda A; Cobelli S; Scanni A Cancer Detect Prev; 1994; 18(3):209-20. PubMed ID: 8076383 [TBL] [Abstract][Full Text] [Related]
19. The diagnostic and prognostic value of ProGRP in lung cancer. Nisman B; Biran H; Ramu N; Heching N; Barak V; Peretz T Anticancer Res; 2009 Nov; 29(11):4827-32. PubMed ID: 20032442 [TBL] [Abstract][Full Text] [Related]
20. Comparison of changes in the NSE levels with clinical assessment in the therapy monitoring of patients with SCLC. Ebert W; Muley T; Trainer C; Dienemann H; Drings P Anticancer Res; 2002; 22(2B):1083-9. PubMed ID: 12168905 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]